Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive ...
Zacks Investment Research on MSN
SRPT stock surges on promising early results from siRNA programs
Shares of Sarepta Therapeutics SRPT rose 35% on Wednesday after the company announced early clinical data on two experimental ...
19h
Sarepta Therapeutics Shares Early siRNA Data in FSHD and DM1 Trials, Highlights Biomarker Knockdown
Sarepta Therapeutics (NASDAQ:SRPT) presented preliminary clinical data from ongoing phase I/II studies of two investigational ...
At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral ...
Sarepta Therapeutics (NASDAQ:SRPT) stock is up approximately 20% in early trading on Wednesday after the company released its ...
Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its ...
Stocktwits on MSN
MDGL stock surges most in a month on Eli Lilly buyout speculation
Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis. ・The company’s Rezdiffra ...
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the 10 Stocks Investors Are Buying Now. Sarepta Therapeutics soared by ...
Interna Therapeutics, a clinical-stage biopharmaceutical company announced today that it has signed an agreement with the University of Oxford to conduct a Phase IIa human challenge trial evaluating ...
Sarepta Therapeutics is navigating a transition from a profitable rare-disease company to a capital-intensive, multi-platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results